Market‑Driven Surge of Ningbo Menovo Pharmaceutical Co. Ltd.
A Record Trading Volume on March 31
On the morning of March 31, 2026, the Shanghai Stock Exchange registered a trading volume of 1.305 billion yuan for Ningbo Menovo Pharmaceutical Co. Ltd. (ticker: 603538), the highest since August 12, 2025. The share price dipped by 3.76 % during the session, settling at 39.18 CNY—the same figure as the closing price on March 26. Despite the slight decline, the liquidity surged, with a turnover rate of 14.53 %. For comparison, the previous trading day’s volume was only 384 million yuan, indicating a sharp increase in investor interest.
The 7‑Day, 6‑Board Phenomenon
Ningbo Menovo has maintained a streak of six consecutive daily gains over the past seven trading days, a performance that has attracted considerable attention. This “7‑day‑6‑board” status has been repeatedly highlighted in market commentary:
- The stock was cited as a leading performer in the pharmaceutical sector during the A‑share market rebound on March 30, with analysts noting that it had “walked out of a 7‑day‑6‑board” streak.
- In several mid‑morning and early‑afternoon reports, the company’s persistence on the board was underscored as a key driver of the positive sentiment surrounding the broader innovation‑drug and medical‑business themes.
The streak’s endurance is significant given the company’s relatively high price‑to‑earnings ratio of 79.12 and the 52‑week low of 11.4 CNY recorded in April 2025. It suggests that market participants are pricing in expectations beyond the company’s current earnings baseline.
“Heavy‑Hit” Announcement: JH389 Probiotic Capsule
The catalyst behind this sustained momentum can be traced to the late‑night announcement on March 19. Ningbo Menovo’s official Weibo account released a post titled “Heavy‑Hit Announcement: Clinical Data of JH389 Probiotic Capsule Revealed.” The announcement summarized the results of a single‑center, open‑label, self‑control human trial conducted by Ningbo Menovo Tiankang Pharmaceutical Co. Ltd. (a subsidiary). The study evaluated the weight‑loss efficacy and safety profile of the JH389 capsule.
Key takeaways from the announcement include:
- Positive clinical outcomes for weight reduction and a favorable safety profile, reinforcing the product’s potential as a dietary supplement in the burgeoning obesity‑management market.
- The inclusion of GLP‑1 delivery system technology, positioning the product at the intersection of probiotic therapy and metabolic disease treatment.
The timing of the release, combined with the company’s strong track record of “board” gains, amplified investor enthusiasm and contributed to the record trading volume seen the following day.
Broader Market Context
March 30 and March 31 witnessed a general upward trend in the Shanghai Composite Index, which recovered from a previous decline of over 1 % to close above the 3,900‑point level. The innovation‑drug and industrial‑metal sectors also experienced heightened activity, with numerous stocks posting multiple consecutive gains. Amid this backdrop, Ningbo Menovo stood out as a high‑growth pharmaceutical that successfully leveraged a clinical‑trial announcement to fuel sustained investor interest.
Company Profile Snapshot
| Item | Detail |
|---|---|
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Exchange | Shanghai Stock Exchange |
| Currency | CNY |
| Market Cap | 1.20 billion CNY |
| Price (2026‑03‑26) | 39.18 CNY |
| 52‑Week High | 39.18 CNY |
| 52‑Week Low | 11.4 CNY |
| P/E Ratio | 79.12 |
| Primary Products | Pharmaceutical intermediates and active pharmaceutical ingredients, focused on the Chinese market |
| Website | www.menovopharm.com |
Conclusion
The confluence of a high‑profile clinical data release, an unbroken series of daily gains, and a record trading volume positions Ningbo Menovo Pharmaceutical Co. Ltd. as a compelling case study in how strategic communication and robust product pipelines can sustain momentum in a competitive sector. While the company’s valuation remains elevated relative to its earnings, the market’s confidence—reflected in the sustained board streak and substantial liquidity—underscores a belief in the long‑term viability of its product portfolio, particularly the JH389 probiotic capsule and its associated GLP‑1 delivery technology.
